戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              Actuarial 1 and 3 year survival was 88% and 50% respecti
2                                          The actuarial 1, 2, 3, and 4 years patient and graft surviva
3                                          The actuarial 1-, 2-, and 3-year survival rates posttranspla
4                                              Actuarial 1-, 3-, and 5-year overall survival rates were
5 years (range, 1 to 12.9 years), with overall actuarial 1-, 3-, and 5-year survival rates of 70%, 36%,
6                                              Actuarial 1-, 3-, and 5-year survivals were 85%, 60%, an
7 P=NS), early rejection (21 vs. 18%, P=NS) or actuarial 1-year graft survival (96 vs. 90%, P=NS).
8                                              Actuarial 1-year graft survival was 91.7% with sirolimus
9                                              Actuarial 1-year overall survival (OS) and event-free su
10                                          The actuarial 1-year pancreas graft survival was 87% for the
11                                              Actuarial 1-year patient and graft survival were 98.6% a
12                                              Actuarial 1-year patient survival was 91.7% with sirolim
13                                          The actuarial 1-year patient survival was 93% for the PAK gr
14 nths (interquartile range, 3.1-37.1 months), actuarial 1-year survival of 47.6%, and 2-year survival
15 se, and 8 (8%) underwent biopsy only with an actuarial 1-year survival of 88%, 51%, and 47%, respecti
16 ents with a median follow-up of 11 years had actuarial 10- and 15-year overall IBTR rates of 22% and
17                                              Actuarial 10-year disease-free survival was significantl
18 gins of <1 mm, 1 to 9 mm, and >or=10 mm, the actuarial 10-year IBTR rates were 28%, 21%, and 19%, res
19                                          The actuarial 10-year survival rates for the 136 SPKs were 9
20                               Death-censored actuarial 15-year graft survival rate was 56%.
21                                              Actuarial 15-year graft survival was 71% for nonrecurren
22               Estimated 5-year, 10-year, and actuarial 15-year overall patients survival rates were 7
23             For living donor recipients, the actuarial 15-year PS rates were similar between groups.
24                                              Actuarial 15-year survival was 60.6% (95% CI, 56.3%-64.9
25 xperienced BPAR (including borderline), with actuarial 19% (14/75) vs. 18% (13/75) in groups A and B,
26                                              Actuarial 2-, 5- and 10-years overall- and disease-speci
27                                              Actuarial 2-year patient, graft, and rejection-free graf
28                                          The actuarial 2-year rates of locoregional control and disea
29                                              Actuarial 2-year survival for Asians versus whites with
30 tal bone volume of more than 37.3% showed an actuarial 2-year survival of 18%, compared with 82% for
31  followup of 34 months in the survivors, the actuarial 2-year survival was 47%, the median survival w
32                                          The actuarial 20-year patient survival rate was 38%; graft s
33                                              Actuarial 20-year survival was 52% (patient) and 42% (gr
34                                          The actuarial 20-year survival was estimated at 45%.
35  with salvage radiation therapy, the overall actuarial 3- and 5-year PSA relapse-free probabilities w
36                                          The actuarial 3-year cancer-specific survival rate was 57% (
37                                          The actuarial 3-year event-free and overall survival rates w
38    With a median follow-up of 37 months, the actuarial 3-year relapse-free survival rate is 24% for t
39                                          The actuarial 3-year relapse-free survival rate was 30% (95%
40                                The estimated actuarial 3-year survival of patients who survived at le
41                                              Actuarial 3-year survival rate was 30% after FAI and 35%
42                                          The actuarial 3-year survival was 17%.
43                                          The actuarial 4-month risk of death was 8.9%, 1.9%, and 1.2%
44                                          The actuarial 4-year progression-free and overall survivals
45                                          The actuarial 4-year survival rate for the entire group was
46                                              Actuarial 5- and 10-year survival was 52% and 43% (HTV o
47                                          The actuarial 5- and 10-year survivals for patients who unde
48                                              Actuarial 5-year disease-free survival was 75% and five
49 odal disease at presentation had a decreased actuarial 5-year disease-specific (0% v 45%, P =.004), d
50                                              Actuarial 5-year freedom from 2ndINT was 80%.
51                                          The actuarial 5-year local and regional nodal control rates
52                This treatment resulted in an actuarial 5-year local control and overall survival of 1
53                                          The actuarial 5-year overall survival was 58% (95% confidenc
54                                          The actuarial 5-year overall, disease-specific, disease-free
55                                              Actuarial 5-year patient survival was 94% in M and 95% i
56   After a median follow-up of 5.1 years, the actuarial 5-year progression-free survival for all patie
57                                          The actuarial 5-year survival for patients undergoing sphinc
58                                              Actuarial 5-year survival was 42% after resection for IP
59 adversely affect aneurysm-related or overall actuarial 5-year survival.
60 te rejection in A2/A2B to B transplants, the actuarial 7-year death censored graft survival was 72% f
61                                          The actuarial 7-year disease-free survival rates were 81% an
62                                          The actuarial 7-year overall survival rates were 85% for pat
63 on were compared with a previously described actuarial algorithm.
64                      Standard techniques for actuarial analyses of potential prognostic variables (Ka
65                                           In actuarial analysis among the initially medically managed
66                                           By actuarial analysis in newly diagnosed CLL (n = 306), BIR
67                                              Actuarial analysis showed an incremental risk of lead fa
68                                              Actuarial analysis was used to project outcomes of patie
69                                 At the final actuarial analysis when follow-up data were updated (Nov
70                                           On actuarial analysis, freedom from appropriate shock at 1
71                                           By actuarial analysis, the 12-month TLR and MACE rates were
72                                           By actuarial analysis, the TAXUS stent compared with the ba
73 ed with the development of PN by exploratory actuarial analysis.
74  genotypes was determined using Kaplan-Meier actuarial analysis.
75                                        On an actuarial basis, the rate of neoplastic progression was
76 sk category, AA and W men had similar 5-year actuarial bNED rates in favorable (78% v 79%, P: = .91),
77 al clinical results are needed to complement actuarial calculations of important end points from mult
78                          The 10- and 15-year actuarial cause-specific survival rates were 98.1% and 9
79                                          The actuarial chance of not needing chemotherapy (non-lympho
80                                     Based on actuarial characteristics of the 2002 U.S. population, p
81                                          The actuarial complication-free survival rate was 71%.
82                                   The 5-year actuarial cumulative rate of BKVN was 5.6%.
83                                          The actuarial current progression-free survival (PFS) rate a
84                         The dissimilarity of actuarial curves between these two groups is consistent
85                                     Two-year actuarial data showed a 75% local tumor control rate and
86 ced relative to historical controls based on actuarial data.
87                                    Five-year actuarial disease-free and overall survival rates were 8
88 e-year PFS was 22% (95% CI, 12%-32%); 5-year actuarial distant metastasis and locoregional recurrence
89 vival (OS), progression-free survival (PFS), actuarial distant metastasis, and locoregional recurrenc
90                            At 24 months, the actuarial estimate of stable treatment-free remission wa
91                                              Actuarial estimates for OS were calculated using Kaplan-
92 red the FLT3/ITD had worse clinical outcome; actuarial event-free survival (EFS) at 4 years from stud
93                             At 6 months, the actuarial event-free survival (no acute rejection, allog
94                                              Actuarial event-free survival at 5 years was 70% versus
95 s, overall actuarial survival, response, and actuarial event-free survival rates were 62%, 48%, and 2
96 1% with the majority being complete, and the actuarial event-free survival was 58% in 44 treatment-na
97                                     However, actuarial freedom from "heart death" (death or transplan
98                          In early survivors, actuarial freedom from death or transplantation was 93.7
99  patients implanted before 2000, the 4-month actuarial freedom from driveline infections, bloodstream
100                                              Actuarial freedom from parenteral support among survivor
101 eratively (range, 3.6 to 30.6 months) for an actuarial freedom from reoperation of 90% at 7 years.
102 served in the CMT group; in the RT group the actuarial frequency of a second cancer was 16% at 20 yea
103                                              Actuarial graft and patient survival was similar in the
104 gnificant difference between groups in 15-yr actuarial graft survival (GS) and death-censored (DC) GS
105                                              Actuarial graft survival at 1 and 4 years postconversion
106                                          The actuarial graft survival at 6.3 years in the CAD DBMC gr
107 e did not observe significant differences in actuarial graft survival at 8 yr post-transplant between
108                         The 1, 3, and 5 year actuarial graft survival in both living donor kidney aft
109                    There is no difference in actuarial graft survival in the two groups at 10 years (
110                                          The actuarial graft survival in this group of 14 patients wa
111 n follow-up of 31 months, the death-censored actuarial graft survival of dDSA recipients was worse th
112 ransplantation); corresponding 1- and 3-year actuarial graft survival was 88% and 61%.
113                                     Subgroup actuarial graft survival was determined.
114  no significant difference between groups in actuarial graft survival.
115                                   The 8-year actuarial graft survivals for the single- and dual-kidne
116 eriovenous malformations, but with increased actuarial hemorrhage rates from the first to the fifth y
117  of these factors was associated with 5-year actuarial IBTR-free and LRR-free survival rates of 87% t
118                                              Actuarial in-field local control rates at one and two ye
119 ths, 20 patients developed t-MDS/AML, for an actuarial incidence of 6.8% at 10 years.
120 low-risk patients who were not screened, the actuarial incidence of an IHD event after listing (befor
121                                   The 2-year actuarial incidence of grade 3 to 5 radiation necrosis w
122 ter sparing procedure was 10% and the 5-year actuarial incidence was 13%.
123                Kaplan-Meier estimates of the actuarial incidence, which are based on censoring of pat
124          Observed survival was calculated by actuarial life table methods for three new node-positive
125                                              Actuarial local control at one and two years after SBRT
126                                   The 5-year actuarial local control rate was 94% (95% CI, 86% to 100
127                                              Actuarial local control rates of the 277 patients treate
128 for all patients), the overall 3- and 5-year actuarial local recurrence rates were 11% and 13%, respe
129 disease treated at M.D. Anderson, the 5-year actuarial local recurrence-free, distant recurrence-free
130                                   The 3-year actuarial locoregional control was 82% and the 3-year ac
131 zed survival of both blacks and whites using actuarial measures; presented outcomes within stage, adj
132 er a median follow-up time of 53 months, the actuarial median survival time of all eligible patients
133                                   The 5-year actuarial metastasis-free survival estimates (SE) were 9
134 k group, PSA outcome was estimated using the actuarial method of Kaplan and Meier.
135   Overlooked is the question of whether such actuarial methods are in fact mathematically justified,
136 st-feeding at 12 months was determined using actuarial methods.
137                                          The actuarial mortality rate was substantially lower among p
138 undergo transplantation or pump replacement, actuarial mortality was 48.2% (95% CI, 31.6 to 65.2) in
139                                      Overall actuarial one-year survival was 90%, and five-year survi
140  women with a first or only BC (BC-1 group), actuarial OS and CSS were compared, accounting for age,
141 onths, median actuarial PFS is 17 months and actuarial OS is 92 months.
142 and median OS was 47.4 months; 5 and 10-year actuarial OS probabilities were 43% and 34%, respectivel
143               Our data suggests that 15-year actuarial outcome (GS and DC GS) is worse for those deve
144                      We analyzed the 15-year actuarial overall patient survival (PS), graft survival
145 w-up of 36 months (range, 18-60 months), the actuarial overall survival (OS) rates at 3 years were 34
146                                          The actuarial overall survival and event-free survivals at 2
147                                          The actuarial overall survival at 14 months was 53%, with a
148                                              Actuarial overall survival for the 1-, 2- and 3-year per
149 uing smokers (18 v 13.6 months), with 5-year actuarial overall survival of 8.9% versus 4%, respective
150                                              Actuarial overall survival was calculated with Kaplan-Me
151                                              Actuarial overall survivals at 1-, 3-, and 5-year for th
152                                              Actuarial pancreas graft survival for SPK recipients at
153                       In this series, 1-year actuarial patient and allograft survival rates are 100%
154                                    Four-year actuarial patient and graft survival for the DBMC-infuse
155                                              Actuarial patient and graft survival rates at 10 years w
156                               Overall 5-year actuarial patient and graft survival rates were 100% ver
157                                   Three-year actuarial patient and graft survival rates were 95% and
158                                     One-year actuarial patient and graft survival was 97% and 92%, re
159                                   Eight-year actuarial patient and graft survivals in older individua
160                          The overall 20-year actuarial patient and graft survivals were 35.8% and 32.
161                          The overall 20-year actuarial patient and graft survivals were 35.8% and 32.
162                        Overall 1- and 3-year actuarial patient and liver allograft survival was 88% a
163                                   Three-year actuarial patient and primary graft survival were 88% an
164 nance immunosuppression had excellent 4-year actuarial patient survival (92%), graft survival (90%),
165                                              Actuarial patient survival at 1 and 3 years for group 1
166                                   Similarly, actuarial patient survival at 10 years is 86% in both gr
167                                          The actuarial patient survival rate at 3 years was 88%, and
168                                     Two-year actuarial patient survival was 95% and 97%, and graft su
169                                   The 8-year actuarial patient survivals for the single- and dual-kid
170                    The 39-month Kaplan-Meier actuarial patient survivals were 75.1% for CLTx and 88.6
171                                   The 1-year actuarial patient, kidney, and pancreas survival rates i
172                                              Actuarial patient/graft survival at 48 months was 96%/91
173                                     One-year actuarial patient/graft survival was 100%/100% in SPK, P
174                                   Three-year actuarial patient/pancreas graft survival rates for SPK,
175 n potential follow-up of 28.3 months, median actuarial PFS is 17 months and actuarial OS is 92 months
176                                              Actuarial-predicted life expectancy, based on age and se
177             The primary end point was 2-year actuarial primary tumor control; secondary end points we
178                                          The actuarial probability of being alive and in remission at
179  a median follow-up period of 26 months, the actuarial probability of current-event-free-survival at
180                                          The actuarial probability of liver decompensation was lower
181                                          The actuarial probability of PVT was lower in the enoxaparin
182 (69.6%) and 7 in group B (29%) survived; the actuarial probability of survival at day 60 was 66% vers
183                                          The actuarial probability of survival was higher in the enox
184                                          The actuarial progression-free survival of 62% at 4 years is
185                                       Median actuarial progression-free survival was 34 months.
186 an follow-up of 42 months, the 3- and 4-year actuarial progression-free survivals were 71% and 62%, r
187 s no difference between groups in subsequent actuarial PS, GS, and DCGS.
188                                   The 4-year actuarial PSA relapse-free survival, distant metastasis-
189 9-43]), 44 (34%) had local regrowths (3-year actuarial rate 38% [95% CI 30-48]); 36 (88%) of 41 patie
190                                   The 4-year actuarial rate of DID was 13.5%.
191  locoregional control was 82% and the 3-year actuarial rate of distant metastases was 19%.
192 lysis, factors significantly associated with actuarial rate of first CVA included hypertension (P = .
193 tionships between potential risk factors and actuarial rate of first stroke were analyzed.
194                                          The actuarial rate of overall survival at 12 years was 76.3%
195                                          The actuarial rate of R01 award attainment at 5 years was 22
196                              By week 50, the actuarial rate of treatment failure was 30.6% in the com
197                                              Actuarial rates of acute GVHD were 46% +/- 13% for grade
198                             Crude and 2-year actuarial rates of BM were 19% and 30%, respectively.
199                                   The 2-year actuarial rates of elective nodal control and primary tu
200                                   The 5-year actuarial rates of freedom from treatment failure (FFTF)
201                                    Five-year actuarial rates of IBTR-free and LRR-free survival were
202                                              Actuarial rates of LR were calculated by using the Kapla
203                           The 5- and 10-year actuarial rates of LRR were both 27%.
204 ce rate was 10.3% (23 of 223), with a 5-year actuarial recurrence-free rate of 0.84 +/- 0.03.
205  was 2.3% (two of 86), resulting in a 5-year actuarial recurrence-free rate of 0.96 +/- 0.03.
206 e Kaplan-Meier method was used to assess the actuarial recurrence-free survival on patients with graf
207 ined rejection-free during follow-up with an actuarial rejection-free probability of 75% within 3 mon
208                                 11 patients (actuarial relapse at 5 years 5.6%, 95% CI 2.3-8.9) given
209                                              Actuarial renal allograft survival rates were 53% at 1 a
210                                          The actuarial risk for this complication has been estimated
211 eatment-related parameters, crude and 2-year actuarial risk of BM were 27% and 39%, respectively, in
212                                              Actuarial risk of death from stage I breast cancer at 7
213    Twenty-five years after HD diagnosis, the actuarial risk of developing a solid tumor was 21.9%.
214 ed patients, progression-free survival (PFS; actuarial +/- SE) was 61% +/- 7% and survival was 58% +/
215                                          The actuarial senescence (i.e., the rate of increase in adul
216     While previous research has demonstrated actuarial senescence in this population, as does this st
217                           Recent examples of actuarial senescence in wild insect populations have cha
218                   Among families of mammals, actuarial senescence was related to extrinsic mortality
219  terminal investment can produce a signal of actuarial senescence.
220 n mechanisms that postpone physiological and actuarial senescence.
221 can evolve in the absence of reproductive or actuarial senescence; this implies that maternal effect
222                                              Actuarial survival after completed stage 2 was 71% at 5
223                                    Estimated actuarial survival after continuous-flow left ventricula
224                                    Five-year actuarial survival after heart transplantation was 58%.
225                                              Actuarial survival among these surgically salvaged patie
226                                              Actuarial survival analysis using Kaplan-Meier curves, C
227 ogistic regression analysis and Kaplan-Meier actuarial survival analysis.
228 l for the entire group was 9 months, and the actuarial survival at 1 and 2 years was 42% and 23%, res
229  is 366 days (95% CI 185, not estimable) and actuarial survival at 1 year is 52%.
230                                              Actuarial survival at 1 year was 55%, progression-free s
231                                              Actuarial survival at 1, 5, and 10 years for Group I was
232                                              Actuarial survival at 10 years from diagnosis of second
233                                              Actuarial survival at 10 years was 97% (SD 2) in the aut
234                                              Actuarial survival at 3 years was 70%, and 3-year event-
235 atients (6%) died from lymphoma; the overall actuarial survival at 3 years was 95%.
236                                              Actuarial survival at 5 and 10 years was 72.4% (95% conf
237     There was no perioperative mortality and actuarial survival at 5 years was 94.6%.
238                                              Actuarial survival at 5, 10, 15, and 20 years was 93% (9
239                                      Overall actuarial survival at 7 years was 55%.
240                                              Actuarial survival at two years was 98.2% among patients
241                                              Actuarial survival curves were plotted according to the
242                          The overall 20-year actuarial survival for pediatric liver transplantation i
243                                     Two-year actuarial survival for the induction group was 93.2% com
244 re no significant differences in the 10-year actuarial survival from transplant between groups.
245             For the validation cohort 2, the actuarial survival from transplant for the M+ group was
246 had a 90-day mortality of 39.7% and a 1-year actuarial survival of 54.5% compared with 6.9% and 88.6%
247                                              Actuarial survival of BK-positive grafts was worse than
248                                              Actuarial survival on support was 72% (95% confidence in
249                       The 1-, 3-, and 5-year actuarial survival rate differed between the study and c
250                                          The actuarial survival rate for the total population was 75%
251 2) with 2 late deaths (1.6%), for an overall actuarial survival rate of 96.3% at 7 years.
252 he median survival was 17 months, and 2-year actuarial survival rate was 40% (95% confidence interval
253 an, 40 years; range, 20-44 years) the 5-year actuarial survival rate was 87.5% (95% CI, 86.5%-88.4%)
254                                          The actuarial survival rate was 90% at 5 years, freedom from
255                                   The 5-year actuarial survival rate was 96.7% (95% CI, 94.1%-99.3%)
256                          One-year and 5-year actuarial survival rates are high, approximately 75% and
257 ts with continuous-flow devices had superior actuarial survival rates at 2 years (58% vs. 24%, P=0.00
258                                              Actuarial survival rates at 6 years were as follows: JMM
259 Differences were found in 1-, 3-, and 5-year actuarial survival rates between the I-CC subgroup and t
260                                          The actuarial survival rates for 1, 3, and 5 years for group
261                                    Five-year actuarial survival rates for all exposure groups, age-ad
262                                   The 5-year actuarial survival rates for more pediatric-specific can
263 tire group was 13 months, with 1- and 2-year actuarial survival rates of 61% and 29%, respectively.
264                       The 1-, 2-, and 3-year actuarial survival rates of all 150 patients were 54%, 1
265                                              Actuarial survival rates related to prognostic determina
266 applicator (5 cm or 6 cm), the 2- and 3-year actuarial survival rates were 27% and 17%, respectively.
267  entire group was 14.4 months; 1- and 2-year actuarial survival rates were 57% and 25%, respectively.
268                            One and five-year actuarial survival rates were 85%/64% for adult and 90%/
269                                              Actuarial survival rates were 91% at 1 year, 88% at 3 ye
270 f 13.3 years, the 10-, 20-, 30-, and 40-year actuarial survival rates were 93%, 79%, 59%, and 26%, re
271                                              Actuarial survival rates were 93.3%, 86.4%, and 73.5% at
272 llow-up of 29 months, the 1-, 3-, and 5-year actuarial survival rates were 97%, 74%, and 58%; median
273                                              Actuarial survival rates were much lower for blacks than
274                                   Three year actuarial survival revealed no difference between groups
275                                 Kaplan-Meier actuarial survival was 24 months, with actual 3 and 5 ye
276 who underwent curative resection, the 5-year actuarial survival was 41%, with a median survival of 48
277                                              Actuarial survival was 60+/-12% versus 92+/-5% (P<0.005)
278 , median actuarial TTP was 43 wk, and median actuarial survival was 70 wk.
279                                          The actuarial survival was 70% at 5 years and the aneurysm-r
280 tor of increased all-cause mortality: 1 year actuarial survival was 79 +/- 5% in the nonfrail group c
281                  The 5-year disease-specific actuarial survival was 79% (78% for patients treated fro
282                     At 10 years, the overall actuarial survival was 88%, the response rate was 71% wi
283                 The overall 4-year estimated actuarial survival was 89% (95% CI 82-94).
284                                              Actuarial survival was 97% and 90% (P=0.30), and surviva
285                                              Actuarial survival was calculated using the Kaplan-Meier
286                                         When actuarial survival was estimated, cohorts with < or = 25
287                                              Actuarial survival was greater in the MMF group compared
288 tcome between matched groups, but the 5-year actuarial survival was higher in patients with thromboly
289                                              Actuarial survival was measured from the initiation of r
290                                              Actuarial survival with freedom from parenteral support
291                         The 4-year estimated actuarial survival with native liver was 51% (42-59%).
292 fully rescued with retransplantation (30-day actuarial survival, 97.1% SLD vs. 94.1% LRD, P=0.745).
293                                   The 5-year actuarial survival, disease-free survival, and bNED rate
294 clophosphamide therapy; at 10 years, overall actuarial survival, response, and actuarial event-free s
295  perioperative mortality (chi(2)) and 5-year actuarial survival.
296 fe expectancy of the general population from actuarial tables: 80 to 84 years (7 years) and > or =85
297 e 27 patients who could be evaluated, median actuarial TTP was 43 wk, and median actuarial survival w
298 nce rate was 5.4% (13 of 242), with a 5-year actuarial tumor recurrence-free rate of 0.88 +/- 0.03.
299 estimate the cumulative incidence over time (actuarial v cumulative calculations), up to 10% of NHL p
300                                          The actuarial yearly failure rate was 2.3% for non-Fidelis a

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top